Alnylam Pharmaceuticals Inc (ALNY)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Alnylam Pharmaceuticals Inc chart...

About the Company

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

CEO

John Maraganore

Exchange

NASDAQ

Website

https://www.alnylam.com/

$187M

Total Revenue

2K

Employees

$19B

Market Capitalization

-41.55

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALNY News

Alnylam Pharmaceuticals

1d ago, source: Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript

1mon ago, source: Hosted on MSN

Alnylam Pharmaceuticals, Inc isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by.

Alnylam Pharmaceuticals Inc ALNY

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges

on MSN ago, source:

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) said the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic ...

Alnylam Pharmaceuticals, Inc.: Alnylam Earnings: Robust Uptake of Amvuttra Drives Sales; Shares Undervalued

27d ago, source: Yahoo Finance

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and ...

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

5d ago, source: Business Wire

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program designed to ...

Alnylam Pharmaceuticals files patent for RNAi agents targeting complement factor b gene

7d ago, source: Pharmaceutical Technology

Discover how Alnylam Pharmaceuticals is revolutionizing treatment for CFB-associated diseases with their innovative RNAi agents targeting the complement factor B gene.

Alnylam Pharmaceuticals Stock (NASDAQ:ALNY), Quotes and News Summary

21d ago, source: Benzinga.com

Roche/Alnylam Blood Pressure Drug Aces In Mid ... the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve ...

Buy Rating Affirmed for Alnylam Pharma Amid Positive Clinical Trials and Strategic Collaborations

13d ago, source: Business Insider

Begin your TipRanks Premium journey today. Alnylam Pharma (ALNY) Company Description: Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development ...

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

5d ago, source: Stockhouse

Patient Advocacy and Engagement at Alnylam Pharmaceuticals. “The Family Health History Road Trip program underscores Alnylam’s commitment to supporting improved health outcomes for the ...

Alnylam Pharmaceuticals Inc ALNY

22d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...